[在抗凝剂治疗期间,基洛斯塔对囊警告综合征有效:病例报告]
Ayane Kawatake1, Hiroyuki Kawano1, Yuko Honda1
1Department of Stroke and Cerebrovascular Medicine, Kyorin University.
Rinsho shinkeigaku = Clinical neurology
|February 18, 2024
概括
这项研究报告了一个病人的病例,该病人在心血管栓塞性中风后经历了反复的过渡性缺血性发作. 囊警告综合征 (CWS) 被诊断出并得到有效的治疗.
科学领域:
- 神经学 神经学
- 心脏病学 心脏病学
- 血管医学 血管医学
背景情况:
- 心血管血栓性中风是导致残疾的重要原因之一.
- 即使在适当的抗凝治疗后,也可能发生复发性缺血事件.
- 囊警告综合征 (CWS) 的特点是经常出现的短暂的神经缺陷.
研究的目的:
- 描述一种与急性心血管栓塞性中风并存的CWS病例.
- 在这种情况下,评估西洛斯塔在治疗CWS方面的疗效.
主要方法:
- 一个88岁的女性患者的病例报告.
- 诊断左中脑动脉M2封闭性中风的诊断.
- 用静脉注射RT-PA和直接口服抗凝药进行治疗.
- 观察复发的短暂半衰,表明CWS.
- 用于CWS管理的西洛斯塔的管理.
主要成果:
- 患者最初在心血管栓塞性中风后得到rt-PA后的改善.
- 尽管服用抗凝血药物,但发生了反复的短暂右半,表明CWS.
- 基洛斯塔的使用导致了进一步过渡性神经事件的停止.
- 这表明CWS可以与急性心血管血栓性中风共存.
结论:
- 囊警告综合征可能发生在急性心血管血栓性中风患者中.
- 奇洛斯塔在预防CWS中复发的短暂神经系统恶化方面表现出有效性.
- 这一案例凸显了在中风患者中识别和管理CWS的重要性.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
523
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
523
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
513
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
513
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166
Anticoagulant Drugs: Low-Molecular-Weight Heparins
697
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
697
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K


